title: Homocysteine pre-treatment increases redox capacity in both endothelial and tumor cells.
abstract: OBJECTIVE
  We studied the modulatory effects of homocysteine pre-treatment on the disulfide reduction capacity of tumor and endothelial cells.
  
  
  METHODS
  Human MDA-MB-231 breast carcinoma and bovine aorta endothelial cells were pre-treated for 1-24 hours with 0.5-5 mM homocysteine or homocysteine thiolactone. After washing to eliminate any rest of homocysteine or homocysteine thiolactone, cell redox capacity was determined by using a method for measuring disulfide reduction.
  
  
  RESULTS
  Homocysteine pre-treatments for 1-4 hours at a concentration of 0.5-5 mM increase the disulfide reduction capacity of both tumor and endothelial cells. This effect cannot be fully mimicked by either cysteine or homocysteine thiolactone pre-treatments of tumor cells.
  
  
  CONCLUSIONS
  Taken together, our data suggest that homocysteine can behave as an anti-oxidant agent by increasing the anti-oxidant capacity of tumor and endothelial cells.
authors.affiliation: a Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Díaz-Santiago
authors.affiliation: a Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Rodríguez-Caso
authors.affiliation: a Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.|b Research Support Central Services (SCAI) of the University of Málaga , Spain.
authors.forename: Casimiro
authors.initials: C
authors.lastname: Cárdenas
authors.affiliation: a Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
authors.forename: José J
authors.initials: JJ
authors.lastname: Serrano
authors.affiliation: a Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.|c CIBER de Enfermedades Raras (CIBERER) , E-29071 Málaga , Spain.
authors.forename: Ana R
authors.initials: AR
authors.lastname: Quesada
authors.affiliation: a Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.|c CIBER de Enfermedades Raras (CIBERER) , E-29071 Málaga , Spain.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Medina
mesh_terms: D000975:Antioxidants / Q000378:metabolism; D045744:Cell Line, Tumor; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006710:Homocysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects
chemical_list: D000975:Antioxidants; D006710:Homocysteine; C007957:homocysteine thiolactone
keywords: Bovine aortic endothelial cells; Cysteine; Homocysteine; Homocysteine thiolactone; MDA-MB231 breast cancer cell; Redox